CohBar, Inc. (CWBR)
OTCMKTS: CWBR · Delayed Price · USD
0.800
-0.100 (-11.15%)
Apr 24, 2024, 1:54 PM EDT - Market closed
Company Description
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases.
It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases.
CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.
CohBar, Inc.
| Country | Canada |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Pinchas Cohen Dean, M.D. |
Contact Details
Address: 1455 Adams Drive, Suite 2050, Menlo Business Park Menlo Park, California 94025 United States | |
| Phone | (650) 446-7888 |
| Website | cohbar.com |
Stock Details
| Ticker Symbol | CWBR |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001522602 |
| CUSIP Number | 19249J109 |
| ISIN Number | US19249J3077 |
| Employer ID | 26-1299952 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pinchas Cohen Dean, M.D. | Founder and Member of Scientific Advisory Board |
| Dr. Nir Yacov Barzilai M.D. | Founder and Member of Scientific Advisory Board |
| Dr. John M. Amatruda M.D., Ph.D. | Co-Founder |
| Jordyn Tarazi | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 27, 2023 | 25-NSE | Filing |
| Nov 27, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 8-K | Current Report |
| Nov 1, 2023 | 8-K | Current Report |
| Oct 25, 2023 | 425 | Filing |
| Oct 25, 2023 | 8-K | Current Report |
| Oct 6, 2023 | 425 | Filing |
| Oct 6, 2023 | 8-K/A | [Amend] Current report |
| Oct 4, 2023 | 425 | Filing |
| Oct 4, 2023 | 8-K | Current Report |